Research and Markets (http://www.researchandmarkets.com/reports/c91788) has announced the addition of “European Markets for Fibromyalgia Syndrome†to their offering.
This research explores the market for therapeutics that are developed for the treatment of Fibromyalgia Syndrome in Europe. It analyses the various challenges faced by the pharmaceutical companies and the competitive advantage of their products in the market.
Key Discussions:
RESEARCH METHODOLOGY
– Research Objective and Scope
Methodology
MARKET OVERVIEW
– Introduction
Disease Characteristics
Epidimeology
– Market Definition and Segmentation
Definition
Segmentation
INDUSTRY CHALLENGES
– Key Challenges
Challenges Faced by the Niche CNS Disorders Markets
TOTAL EUROPEAN MARKETS FOR FIBROMYALGIA SYNDROME
– Overview and Definitions
Market Drivers
Market Restraints
Explored Treatment Options
Unmet Needs
Market Engineering Measurements
– Competitive Analysis
Pfizer
Eli Lilly
Forest/Cypress Bioscience
TOTAL FORECASTS FOR THE EUROPEAN MARKETS FOR FIBROMYALGIA SYNDROME
– Patient and Revenue Forecasts
Patient Population
Revenue Forecasts
STRATEGIC RECOMMENDATIONS
– Recommendations for the European Markets for Fibromyalgia Syndrome.
Recommendations
DATABASE OF KEY INDUSTRY PARTICIPANTS
– Key Market Participants
Companies in the Fibromyalgia Syndrome Market
DECISION SUPPORT DATABASES
– Databases for Analysis
Total Cases of Stroke
Deaths due to Stroke
Total Cases of Epilepsy
Total Cases of Multiple Sclerosis
Deaths due to Epilepsy
Deaths due to Multiple Sclerosis
Companies mentioned:
– Eli Lilly
– Forest/Cypress Bioscience
– Pfizer
For more information visit http://www.researchandmarkets.com/reports/c91788
Research and Markets
Laura Wood, Senior Manager
Fax: +353 1 4100 980
press@researchandmarkets.com
